ABSTRACT
This cross-sectional observational study was conducted to evaluate the implication of CA19-9 level in predicting the extent of hepatic fibrosis in patients with chronic hepatitis B (CHB). Fifty treatment-naive patients with CHB were divided into three groups: group I, patients with no fibrosis (F0; n = 3); group II, patients with mild fibrosis (F1; n = 25) and group III, patients with moderate fibrosis (F3; n = 22). There was no significant (p > 0.05) difference in levels of serum bilirubin, serum alanine aminotransferase, alkaline phosphatase, and alpha fetoprotein among groups I, II and III. Also, mean CA19-9 level did not differ among the three groups. It was observed that, for group II, AUC was 42.6%, sensitivity 52%, specificity 32%, considering cut-off value as 2.8 U/ml to predict F1 liver fibrosis. For group III, AUC was 57.7%, sensitivity 68%, specificity 50% considering cut-off value as 3.2 U/ml to predict F3 fibrosis. The levels of CA19-9 level do not seem to have significant predictive implication to assess hepatic fibrosis. HOW TO CITE THIS ARTICLE: Haque MS, Sultana S, Al-Mahtab M, Al-Mamun A, Rahman S. The Value of Serum CA19-9 Levels in predicting Extent of Hepatic Fibrosis in Patients with Chronic Hepatitis B. Euroasian J Hepato-Gastroenterol 2015;5(1):16-18.
ABSTRACT
Primary biliary cirrhosis (PBC) is very closely associated with the presence of antimitochondrial antibodies (AMA). Nevertheless, 5 to 10% of patients with typical features of primary biliary cirrhosis do not have detectable AMA. They are referred to as AMA negative PBC. We report a case of PBC who was AMA-negative. The patient was a middle-aged woman seeking help of dermatologist for her complaint of itching. The diagnosis was confirmed by histopathology, whereas other possible causes of cirrhosis were excluded. HOW TO CITE THIS ARTICLE: Begum R, Mahtab MA, Mamun AA, Saha BK, Hossain SMS, Saha DC, Akbar SMF, Kamal M, Rahman S. A Case of Antimitochondrial Antibody Negative Primary Biliary Cirrhosis from Bangladesh and Review of Literature. Euroasian J Hepato-Gastroenterol 2015;5(2):122-126.
ABSTRACT
BACKGROUND/AIMS: Percutaneous liver biopsy is a commonly used procedure for management of patients with liver diseases. We studied 107 patients of liver diseases with percutaneous liver biopsy to assess the need and usefulness of post procedure abdominal binder, analgesics, antibiotics or blood transfusion, and safety of the procedure. METHODOLOGY: We selected 107 consecutive patients having clear indication for liver biopsy. Each and every patient underwent percutaneous liver biopsy under uniform technique. The study was performed at the Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh during the period from July 2006 to December 2007. RESULTS: Mean age of the patients was 27.35 years with +/- 7.62 (SD) years. Eighty five of them were male and 22 were female. No abdominal binder or antibiotic was used after the procedure. No analgesic or blood transfusion was required after the procedure. CONCLUSION: Routine post procedure use of abdominal binder and antibiotic are needless. Analgesics and blood transfusion are not always needed after the procedure. Percutaneous liver biopsy is a safe procedure in expert hands.
